Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria.

Predisposition to genital infections and urinary tract infections (UTIs) in type 2 diabetes mellitus (T2DM) results from several factors such as glucosuria, adherence of bacteria to the uroepithelium and immune dysfunction. The tendency to develop these infections could be even higher in patients with T2DM treated with the emerging class of sodium-glucose cotransporter-2 (SGLT2) inhibitors. Studies have shown that pharmacologically-induced glucosuria with SGLT2 inhibitors raises the risk of developing genital infections and, to a relatively lesser extent, UTIs. However, a definitive dose relationship of the incidence of these infections with the SGLT2 doses is not evident in the existing data. Therefore, the precise role of glucosuria as a causative factor for these infections is yet to be fully elucidated.

• Publication year

  2014

• Venue

  Diabetes Research and Clinical Practice

• Publication date

  2014-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.diabres.2013.12.052PMID 24529566
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.

  2013cited by this paper
• Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea

  2013cited by this paper
• A Phase IIb, randomized, placebo‐controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

  2013cited by this paper
• Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double‐blind, placebo‐controlled trial

  2013cited by this paper
• Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia

  2013cited by this paper
• Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study

  2012cited by this paper
• Dapagliflozin monotherapy in drug‐naïve patients with diabetes: a randomized‐controlled trial of low‐dose range

  2012cited by this paper
• Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

  2012cited by this paper
• Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.

  2012cited by this paper
• Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database.

  2012cited by this paper
• Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD).

  2012cited by this paper
• Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

  2012cited by this paper
• Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor

  2012cited by this paper
• Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial

  2011cited by this paper
• Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus

  2011cited by this paper
• Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.

  2010cited by this paper
• Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise

  2010cited by this paper
• Meta-Analysis of the Significance of Asymptomatic Bacteriuria in Diabetes

  2010cited by this paper
• Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

  2009cited by this paper
• Diversity and complexity of urinary tract infection in diabetes mellitus

  2009cited by this paper
• Prevalence of lower urinary tract infection in South Indian type 2 diabetic subjects

  2009cited by this paper
• A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers

  2009cited by this paper
• Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

  2008cited by this paper
• Frequency, risk factors, and responsible pathogenic microorganisms of asymptomatic bacteriuria in patients with type 2 diabetes mellitus.

  2008cited by this paper
• Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome

  2007cited by this paper
• Asymptomatic bacteriuria in women with diabetes mellitus: effect on renal function after 6 years of follow-up.

  2006cited by this paper
• Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors.

  2006cited by this paper
• Incidence and risk factors associated with urinary tract infection in diabetic patients with and without asymptomatic bacteriuria

  2006cited by this paper
• Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults.

  2005cited by this paper
• Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus.

  2003cited by this paper
• Adherence of type 1-fimbriated Escherichia coli to uroepithelial cells: more in diabetic women than in control subjects.

  2002cited by this paper
• Prevalence of urinary tract infection and renal scars in patients with diabetes mellitus.

  2001cited by this paper
• Cytokine secretion is impaired in women with diabetes mellitus.

  2000cited by this paper
• Risk factors for symptomatic urinary tract infection in women with diabetes.

  2000cited by this paper
• Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status.

  2000cited by this paper
• Asymptomatic bacteriuria may be considered a complication in women with diabetes. Diabetes Mellitus Women Asymptomatic Bacteriuria Utrecht Study Group.

  2000cited by this paper
• Cytokine secretion is impaired in women with diabetes mellitus

  2000cited by this paper
• Effect of glucose and pH on uropathogenic and non-uropathogenic Escherichia coli: studies with urine from diabetic and non-diabetic individuals.

  1999cited by this paper
• Impaired Leucocyte Functions in Diabetic Patients

  1997cited by this paper
• Bacterial urinary tract infections in diabetes.

  1997cited by this paper
• In vitro binding of type 1-fimbriated Escherichia coli to uroplakins Ia and Ib: relation to urinary tract infections.

  1996cited by this paper
• Hospitalization for acute pyelonephritis in Manitoba, Canada, during the period from 1989 to 1992; impact of diabetes, pregnancy, and aboriginal origin.

  1996cited by this paper
• Diabetes mellitus and bacteraemia: a comparative study between diabetic and non-diabetic patients.

  1992cited by this paper
• Asymptomatic bacteriuria in patients with diabetes mellitus.

  1991cited by this paper
• Handicaps to Host Defense: Effects of Hyperglycemia on C3 and Candida albicans

  1990cited by this paper
• Neutrophil Sorbitol Production Impairs Oxidative Killing in Diabetes

  1987cited by this paper
• Correlative relationship between adherence of Candida albicans to human vaginal epithelial cells in vitro and candidal vaginitis.

  1984cited by this paper
• Bmc Infectious Diseases Prevalence and Risk Factors for Vaginal Candida Colonization in Women with Type 1 and Type 2 Diabetes

  year unknowncited by this paper

• Predictors of Multidrug-Resistant Urinary Tract Infections in Women: A Large Retrospective Cohort Study in a Romanian University Hospital

  2026cites this paper
• Effect of metabolites on the survival and biofilm formation of Pantoea piersonii (Basionym: Kalamiella piersonii) in synthetic urine media

  2026cites this paper
• Type 2 diabetes mellitus exacerbates vaginal group B Streptococcus colonization via impaired mucosal cytokine response

  2026cites this paper
• Risk of prostatitis in patients with type 2 diabetes mellitus: An observational retrospective cohort study of canagliflozin versus other antihyperglycemic agents using propensity score matching

  2026cites this paper
• Comparative Safety of SGLT2 Versus DPP4 Inhibitors in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.

  2026cites this paper
• Diabetes Mellitus as a Risk Factor for Complicated Urinary Tract Infections in Kidney Transplant Recipients

  2025cites this paper
• Impact of recently initiated medications on the incidence of urinary tract infections in patients with type 2 diabetes: an observational case-control study

  2025cites this paper
• Pros and Cons of Early Treatment with GLP-1 Receptor Agonist and SGLT-2 Inhibitors for Youth with Type 2 Diabetes: A Narrative Review

  2025cites this paper
• The Role of Prognostic Nutritional Index in UTI Susceptibility Among Female Type 2 Diabetic Patients

  2025cites this paper
• A case of pyelonephritis and bacteremia caused by Candida glabrata in a patient on sodium glucose cotransporter 2 inhibitor, successfully treated with micafungin

  2025cites this paper
• Efficacy and safety of 11 sodium-glucose cotransporter-2 inhibitors at different dosages in type 2 diabetes mellitus patients inadequately controlled with metformin: a Bayesian network meta-analysis

  2025cites this paper
• Les infections urinaires : complications fréquentes au cours du diabète

  2025cites this paper
• Treatment Preferences for Novel Type 2 Diabetes Oral Medications: Insights from the Asian Diabetes Patient Preference Study

  2025cites this paper
• Pink semen in a patient with diabetes mellitus an uncommon effect of a common drug:  A case report

  2025cites this paper
• Disproportionality analysis of infection associated with antidiabetic drug use patterns

  2025cites this paper
• Cardiovascular Outcomes of Patients With Type 2 Diabetes With Urinary Tract Infection Post Sodium-Glucose Cotransporter 2 Inhibitors Treatment: A Multicenter Observational Study.

  2025cites this paper
• Use of SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Urinary Tract Infection: Is There a Need for Concern?

  2025cites this paper
• Therapeutic management of PI3Kα inhibitor-induced hyperglycemia with a novel glucokinase activator: Advancing the Frontier of PI3Kα inhibitor therapy

  2025cites this paper
• A personalized prediction model for distinguishing between asymptomatic bacteriuria and symptomatic urinary tract infections in patients with type 2 diabetes mellitus using machine learning

  2025cites this paper
• Identification of Escherichia coli in Patients with Diabetes Mellitus Suspected of Urinary Tract Infection Complications at the Imbanagara Health Center, Ciamis Regency

  2025cites this paper
• Patient education and monitoring of sodium-glucose co-transporter 2 inhibitors in diabetes

  2025cites this paper
• Resistance Patterns of Urinary Tract Pathogens Isolated from Patients with Type 2 Diabetes Mellitus on Sodium Glucose Co-transporter 2 Inhibitors Admitted in a Tertiary Hospital in the Philippines: A Single-Center Retrospective Cohort Study

  2025cites this paper
• Evaluating the Risk Factors and Bidirectional Association of Urinary Tract Infections in Diabetes Mellitus

  2025cites this paper
• SGLT2 Inhibitors and External Genital Infection in Male Patients With Type 2 Diabetes

  2025cites this paper
• Risk of genitourinary tract infections with SGLT-2 inhibitors in type 2 diabetes mellitus: A meta-analysis of randomised controlled trials and disproportionality analysis using FAERS

  2025cites this paper
• SGLT2 Inhibitors and the Risk of Urogenital Infections: A Concise Review

  2025cites this paper
• Pharmacological mechanisms and clinical applications between SGLT1 and SGLT2 inhibitors in type 2 diabetes and diabetic kidney disease: An analytic review.

  2025cites this paper
• Pros and Cons of Inpatient SGLT2i Use for Hyperglycemia and Heart Failure

  2025cites this paper
• Effects of sodium-glucose co-transporter-2 inhibitors on the risk of nephrolithiasis and urinary tract infections in Thai patients with type 2 diabetes: a hospital-based cohort study

  2025cites this paper
• Correlating Urinary Tract Infection Risks With Sodium-Glucose Cotransporter-2 Inhibitors: Insights From the National Health Insurance Data of Korea

  2025cites this paper
• Comparative efficacy and safety of oral hypoglycaemic drugs as adjunctive therapy in the management of type 1 diabetes mellitus: A systematic review and meta‐analysis

  2025cites this paper
• Efficacy and Safety of Enavogliflozin as Add-on in Adults with Type 2 Diabetes Mellitus Inadequately Controlled with Insulin or Insulin with Other Antidiabetic Drugs.

  2025cites this paper
• Comparative risk of infection of medications used for type 2 diabetes

  2024cites this paper
• Genito Urinary Infection and Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Receiving SGLT2 Inhibitors: Evidence from a Systematic Literature Review of Landmark Randomized Clinical Trial

  2024cites this paper
• Advances in SGLT2 Inhibitors for Type 2 Diabetes Management

  2024cites this paper
• Prevalence of genitourinary symptoms in people with type 2 diabetes initiated with SGLT2 inhibitors

  2024influential citation
• Urinary Tract Infections and Fungal Infections Associated with Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors and Metformin Combination: A Real-World Study from 2013 to 2023 Based on the FDA Adverse Event Reporting System (FAERS) Database

  2024cites this paper
• A Case Study of Emphysematous Cystitis in a Non-diabetic Patient Following Empagliflozin Use: An Uncommon Presentation

  2024cites this paper
• Dual add‐on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study

  2024cites this paper
• Urine microbiome in individuals with an impaired immune system

  2024cites this paper
• Investigation of cardiorenal outcomes and incidence of genitourinary tract infection after combined SGLT2 inhibitor and ACEI/ARB use in patients with chronic kidney disease stages 3-5: A real-world retrospective cohort study in Taiwan

  2024cites this paper
• Comparison of the severity of urinary tract infections between Metformin and SGL2 Inhibitors among Iraqi Type 2 Diabetics.

  2024cites this paper
• A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study

  2024cites this paper
• Drug Safety Evaluation of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Comorbid Patients by Review of Systemic Extraglycemic Effects

  2024cites this paper
• ÜRİNER SİSTEM ENFEKSİYONU OLAN TİP 2 DİABETES MELLİTUS HASTALARINDA SİSTEMİK İMMÜN VE İNFLAMASYON İNDEKSİNİN DEĞERLENDİRİLMESİ

  2024cites this paper
• Cardiovascular Disease Management With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Cardiology Primer

  2024cites this paper
• Efficacy and Safety of SGLT2 Inhibitors in Pediatric Patients and Young Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2024cites this paper
• Insightful Perspectives on Sodium-glucose Co-transporter 2 Inhibitors: Navigating Safety Updates and Beyond.

  2024cites this paper
• A personalized prediction model for urinary tract infections in type 2 diabetes mellitus using machine learning

  2024cites this paper
• Comparing ischemic cardiovascular effectiveness and safety between individual SGLT-2 inhibitors and DPP-4 inhibitors in patients with type 2 diabetes: a nationwide population-based cohort study

  2024cites this paper
• Cutaneous Adverse Drug Reactions Associated with SGLT2 Inhibitors

  2024cites this paper
• Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study

  2024cites this paper
• Incidence and Recurrence of Urinary Tract Infections Caused by Uropathogenic Escherichia coli: A Retrospective Cohort Study

  2024cites this paper
• Risk of acute pancreatitis among new users of empagliflozin compared to sulfonylureas in patients with type 2 diabetes: A post‐authorization safety study

  2024cites this paper
• Cardio-renal protective effect and safety of sodium-glucose cotransporter 2 inhibitors for chronic kidney disease patients with eGFR < 60 mL/min/1.73 m2: a systematic review and meta-analysis

  2024cites this paper
• Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study

  2023cites this paper
• Evaluation of Risk Factors for Fever and Sepsis after Ureteroscopic Lithotripsy: A Prospective Observational Study

  2023cites this paper
• Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease: a systematic review and meta-analysis

  2023cites this paper
• Particularities of Urinary Tract Infections in Diabetic Patients: A Concise Review

  2023influential citation
• SGLT2 Inhibitors’ Cardiovascular Benefits in Individuals Without Diabetes, Heart Failure, and/or Chronic Kidney Disease: A Systematic Review

  2023cites this paper
• Exploring the Use of Diabetic Medications for Non-Diabetic Conditions: A Comprehensive Literature Review

  2023cites this paper
• BALANOPOSTHITIS/BALANITIS ASSOCIATION IN CASE OF UNCONTROLLED T2DM WHO HAVE ATTENDING TERTIARY CARE HOSPITAL

  2023cites this paper
• The results of SGLT-2 inhibitors use in kidney transplantation: 1-year experiences from two centers

  2023cites this paper
• Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial

  2023cites this paper
• Diabetes Mellitus and the Kidneys.

  2023cites this paper
• Prevalence of genitourinary infection in diabetic patients treated with SGLT 2 inhibitors

  2023cites this paper
• Comparison of SGLT1, SGLT2, and Dual Inhibitor Biological Activity in Treating Type 2 Diabetes Mellitus

  2023cites this paper
• Sickeningly Sweet: Infectious Complications of Diabetes

  2023cites this paper
• Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial

  2022cites this paper
• The Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients

  2022cites this paper
• Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting

  2022cites this paper
• Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea

  2022cites this paper
• SGLT2 Inhibitors and Safety in Older Patients.

  2022cites this paper
• Insights from the molecular docking analysis of SGLT2 and FIMH to combat uropathogenicity

  2022cites this paper
• Efficacy and safety of SGLT-2i in overweight/obese, non-diabetic individuals: a meta-analysis of randomized controlled trials.

  2022cites this paper
• Sodium–glucose cotransporter 2 inhibitor-associated severe epididymo-orchitis

  2022cites this paper
• [Effect of Empagliflozin on Candida glabrata Adhesion to Vaginal Epithelial Cells].

  2022cites this paper
• Protective effect of empagliflozin on gentamicin-induced acute renal injury via regulation of SIRT1/NF-κB signaling pathway.

  2022cites this paper
• Urease-negative uropathogen Kalamiella piersonii YU22 metabolizes urea by urea carboxylase and allophanate hydrolase enzyme system.

  2022cites this paper
• Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations

  2022cites this paper
• Prevalence of Bacterial Urinary Tract Infections Amongst Diabetes Mellitus Patients Attending Ibn-sina General Hospital in Mukalla, Yemen

  2022cites this paper
• SGLT2 Inhibitors: A Broad Impact Therapeutic Option for the Nephrologist

  2022cites this paper
• Incidence and Factors associated with Genitourinary Infections among Type 2 Diabetes patients on SGLT2 Inhibitors: A single retrospective cohort study

  2022cites this paper
• Systematic Review of Literature Examining Bacterial Urinary Tract Infections in Diabetes

  2022cites this paper
• Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials

  2022cites this paper
• Medications Associated with Occurrence of Urinary Tract Infections in Patients with Diabetes, Heart Failure or Both.

  2022cites this paper
• Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study

  2022cites this paper
• Efficacy and safety of sodium-glucose co-transporter 2 inhibitors in the elderly versus non-elderly patients with type 2 diabetes mellitus: a meta-analysis.

  2022cites this paper
• Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently

  2022cites this paper
• Increased risk of urinary tract infection and pyelonephritis under concomitant use of sodium‐dependent glucose cotransporter 2 inhibitors with antidiabetic, antidyslipidemic, and antihypertensive drugs: An observational study

  2022cites this paper
• Risk factors of first and recurrent genitourinary tract infection in patients withtype 2 diabetes treated with SGLT2 inhibitors: a retrospective cohort study.

  2022cites this paper
• Assessment of Genital and Urinary tract infections in patients with Type 2 Diabetes Mellitus treated with Dapagliflozin

  2022cites this paper
• SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure—A Concise Review

  2022cites this paper
• A Novel Wrapper–Based Feature Selection for Early Diabetes Prediction Enhanced With a Metaheuristic

  2021cites this paper
• Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study.

  2021cites this paper
• Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) as a Primary Preventative Agent in the Healthy Individual: A Need of a Future Randomised Clinical Trial?

  2021cites this paper
• Glycosuria Alters Uropathogenic Escherichia coli Global Gene Expression and Virulence

  2021cites this paper
• Biofilm formation by Candida albicans and Candida glabrata isolated from urine specimens of diabetic Iraqi women

  2021cites this paper
• Covid 19 May Limit The Use of Anti-Hyperglycaemic Agents. Does It Call for The Development of New Anti-Hyperglycaemic Agents?

  2021cites this paper
• Renal Tubular Handling of Glucose and Fructose in Health and Disease.

  2021cites this paper